The FDA has accepted MSD’s doravirine/islatravir new drug application (NDA) for review to treat adults with virologically suppressed HIV-1.

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were ...

The World Health Organisation (WHO) has called for the immediate global rollout of a breakthrough HIV drug, lenacapavir (LEN) ...

A 43-year-old man presents requesting screening for sexually transmitted infections (STIs). His medical history is remarkable for systemic lupus erythematosus (SLE), and he is currently receiving no ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

We’ve come a long way in treating HIV, the virus that can lead to AIDs. Just last month, the FDA approved a medication that is said to have the potential to end the HIV pandemic.The new medication is ...